Ruth Soto-Malave
Infectious Disease · Bayamon, PRNPI 1437125143
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,228 of the $10,794 with a category attached, or 67.0%. 18 manufacturers reported payments, led by Gilead at 53.8% of the total. Reporting peaked in 2022 at $3,589 and has fallen 81.5% since, to $664 in 2025. Among infectious disease clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 238 payments — averaging $45.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$6K
- Viiv Healthcare Company$3K
- Johnson & Johnson$747
- Merck$569
- Janssen Products, LP$299
- EMD Serono, Inc.$192
- plus $563 from 12 others
What the payments were for
- Consulting fees$2,85026%
- Speaking & faculty fees$1291%
- Travel & lodging$2893%
- Food & beverage$7,22867%
- Education$2993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 80 | $5,807 |
| Viiv Healthcare Company | 67 | $2,616 |
| Johnson & Johnson(2 entities) | 35 | $747 |
| Merck | 18 | $569 |
| Janssen Products, LP | 3 | $299 |
| EMD Serono, Inc. | 10 | $192 |
| Napo Pharmaceuticals Inc | 9 | $129 |
| TG Therapeutics, Inc. | 1 | $115 |
| Theratechnologies Inc. | 3 | $67 |
| Exact Sciences | 2 | $50 |
| GSK | 2 | $42 |
| Vyera Pharmaceuticals, LLC | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Mylan Institutional Inc. | 1 | $23 |
| PBG Puerto Rico LLC | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,794 in reported general payments places this provider in the 90th percentile of 127 infectious disease providers in Puerto Rico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 38 | $184,288 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 15 | $98,439 |
| TivicayDolutegravir Sodium | 32 | $78,393 |
| DescovyEmtricitabine/Tenofov Alafenam | 21 | $45,972 |
| SynthroidLevothyroxine Sodium | 18 | $937 |
| Rosuvastatin Calcium | 35 | $194 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 17 | $129 |
| Amlodipine Besylate | 15 | $56 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $5,807 | $230,26059 claims |
| Janssen Products, LPSymtuza | $299 | $98,43915 claims |
| Viiv Healthcare CompanyTivicay | $2,616 | $78,39332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 127 infectious disease providers in Puerto Rico.
Other infectious disease in Bayamon
- Joel Munoz CoreanoBayamon$59K
- Bernard Christenson BravoBayamon$11K
- Zelma Fuxench LopezBayamon$4K
- Eduardo Morfa RomeroBayamon$2K
- Patricia Pastor PerezBayamon$2K
- Melba ColonBayamon$847
- Marisel Bosques RosadoHato Rey$247K
- Jorge Santana BagurManati$180K
- Francisco AlvaradoCaguas$69K
- Jorge Bertran-PasarellHato Rey$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.